Partnering with Veracyte to Deliver More Complete Genomic Insights in Prostate Cancer Care

At Helix, we’re focused on solving one of the most pressing challenges in cancer care: how to bring comprehensive genomic insights to every patient, regardless of where they’re treated. Our new partnership with Veracyte, announced today and highlighted in their earnings call, represents a meaningful step forward in this mission.

Through this collaboration, Veracyte will offer Helix’s whole-exome based hereditary cancer test alongside their Decipher® Prostate test, which is widely used for tumor testing in prostate cancer. This integrated approach facilitates access to both tumor and germline data from a single workflow, expanding the insights available to guide diagnosis and treatment.

Why this matters for patients and providers

Germline testing is playing an increasingly important role in cancer care. For patients with metastatic or high-risk localized prostate cancer, National Comprehensive Cancer Network® (NCCN®) guidelines recommend germline genetic testing. Such testing can directly inform treatment choices, including the use of PARP inhibitors (e.g., olaparib, rucaparib). Yet historically, germline testing has remained siloed or underutilized, often due to workflow challenges, reimbursement complexity, or lack of awareness.

By embedding Helix’s test into a trusted clinical workflow already used by thousands of providers, the Veracyte-Helix partnership addresses a known barrier in real-world clinical practice: access. Providers can now order comprehensive hereditary cancer testing, including pharmacogenomics (PGx), if indicated, at the same time as Decipher’s transcriptomic-based tumor analysis. This can help enable more consistent adherence to guidelines and more personalized care for patients.

Beyond informing treatment, germline genetic test results can also:

• Clarify the risk of developing additional cancers
• Support cascade testing for at-risk family members
• Complement pharmacogenomics (PGx) to further personalize therapy decisions

Advancing scalable precision medicine

This collaboration reflects the growing demand for more complete, clinically actionable genomics delivered at scale. It also demonstrates how integrated diagnostics, combining tumor profiling with germline predisposition testing, can be operationalized in urologic oncology settings.

Powered by our Exome+® assay and our Sequence Once, Query Often® model, Helix enables providers to derive long-term value from a single test by giving them the flexibility to request additional panels or indications over time, without requiring a recollection. This helps minimize the costs and delays associated with repeat testing as new clinical questions emerge and medical knowledge evolves.

We’re proud to work with Veracyte to bring this vision to life for more providers and patients. This collaboration underscores how innovation can drive real-world impact when it aligns with clinical needs and care delivery models.

To learn more about our germline oncology offerings or implementation models, visit helix.com.